栄養補助食品のCDMO市場：剤形別、サービス別、企業規模別、地域別、機会、予測、2017年～2031年

世界の栄養補助食品のCDMOの市場規模は、予測期間の2024年～2031年に8.01％のCAGRで拡大し、2023年の352億3,000万米ドルから2031年には652億6,000万米ドルに成長すると予測されています。市場の成長を支えているのは、栄養補助食品の消費量の増加、新商品の発売、顧客基盤の拡大や製造能力の向上に向けた大手企業による投資の増加です。世界のプレゼンスを拡大し、既存拠点での足跡を強化するために、世界中の栄養補助食品のCDMO間で提携、合併、買収が増加していることも、世界の栄養補助食品のCDMO市場を後押ししています。

栄養補助食品開発における技術進歩の増加は、製品需要を増大させる主な要因の1つであり、その結果、栄養補助食品の開発・製造受託機関（CDMO）への依存度が高まっています。新しい送達システムやカプセル化技術など、現在進行中の技術の進歩は栄養補助食品分野に革命をもたらしています。このような技術革新は、栄養補助食品成分の標的送達、生物学的利用能、安定性の向上に役立っており、顧客にとってより魅力的なものとなっています。

さらに、主要な市場参入企業は、世界中のさまざまな地域に拠点を拡大するための助成金や資金の確保にも取り組んでいます。こうした取り組みも、栄養補助食品のCDMO市場に有利な成長機会をもたらすと期待されています。2024年8月、Lonza Group Ltd.は英国の生物製剤サイトのために3,860万米ドル（3,000万ポンド）の助成金を確保しました。科学技術革新省は、助成金制度であるライフサイエンス革新的製造基金に基づき、同社に助成金を交付しました。このような助成金は、研究開発活動や各地域での事業強化に力を注ぐ大手市場プレイヤーを支援するものと期待されます。

当レポートでは、世界の栄養補助食品のCDMO市場について調査し、市場の概要とともに、剤形別、サービス別、企業規模別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の栄養補助食品のCDMO市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 剤形別
  • サービス別
  • 企業規模別
  • 地域別

第5章 北米の栄養補助食品のCDMO市場の見通し、2017年～2031年

第6章 欧州の栄養補助食品のCDMO市場の見通し、2017年～2031年

第7章 アジア太平洋の栄養補助食品のCDMO市場の見通し、2017年～2031年

第8章 南米の栄養補助食品のCDMO市場の見通し、2017年～2031年

第9章 中東・アフリカの栄養補助食品のCDMO市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場参入企業トップ10の情勢
  • Catalent, Inc.
  • Lonza Group Ltd.
  • Robinson Pharma, Inc.
  • Aenova Holding GmbH
  • Soho Flordis International Pty Limited
  • NutraPakUSA
  • International Flavors & Fragrances Inc. (Health Wright Products)
  • NutraScience Labs
  • INPHARMA S.p.A.
  • INW Manufacturing, LLC

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 3. Global Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 4. Global Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 5. Global Nutraceuticals CDMO Market Share (%), By Region, 2017-2031F
• Figure 6. North America Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 8. North America Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 9. North America Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 10. North America Nutraceuticals CDMO Market Share (%), By Country, 2017-2031F
• Figure 11. United States Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 13. United States Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 14. United States Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 15. Canada Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 17. Canada Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 18. Canada Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 19. Mexico Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 21. Mexico Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 22. Mexico Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 23. Europe Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 25. Europe Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 26. Europe Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 27. Europe Nutraceuticals CDMO Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 30. Germany Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 31. Germany Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 32. France Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 34. France Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 35. France Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 36. Italy Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 38. Italy Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 39. Italy Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 40. United Kingdom Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 42. United Kingdom Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 43. United Kingdom Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 44. Russia Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 46. Russia Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 47. Russia Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 48. Netherlands Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 50. Netherlands Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 51. Netherlands Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 52. Spain Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 54. Spain Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 55. Spain Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 56. Turkey Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 58. Turkey Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 59. Turkey Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 60. Poland Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 62. Poland Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 63. Poland Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 64. South America Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 66. South America Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 67. South America Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 68. South America Nutraceuticals CDMO Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 71. Brazil Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 72. Brazil Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 73. Argentina Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 75. Argentina Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 76. Argentina Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 77. Asia-Pacific Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 79. Asia-Pacific Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 80. Asia-Pacific Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 81. Asia-Pacific Nutraceuticals CDMO Market Share (%), By Country, 2017-2031F
• Figure 82. India Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 84. India Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 85. India Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 86. China Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 88. China Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 89. China Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 90. Japan Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 92. Japan Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 93. Japan Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 94. Australia Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 96. Australia Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 97. Australia Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 98. Vietnam Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 100. Vietnam Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 101. Vietnam Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 102. South Korea Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 104. South Korea Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 105. South Korea Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 106. Indonesia Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 108. Indonesia Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 109. Indonesia Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 110. Philippines Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 112. Philippines Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 113. Philippines Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 114. Middle East & Africa Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 116. Middle East & Africa Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 117. Middle East & Africa Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 118. Middle East & Africa Nutraceuticals CDMO Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 121. Saudi Arabia Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 122. Saudi Arabia Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 123. UAE Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 125. UAE Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 126. UAE Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 127. South Africa Nutraceuticals CDMO Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Nutraceuticals CDMO Market Share (%), By Dosage Form, 2017-2031F
• Figure 129. South Africa Nutraceuticals CDMO Market Share (%), By Service, 2017-2031F
• Figure 130. South Africa Nutraceuticals CDMO Market Share (%), By Company Size, 2017-2031F
• Figure 131. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By Company Size Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global nutraceuticals CDMO market is projected to witness a CAGR of 8.01% during the forecast period 2024-2031, growing from USD 35.23 billion in 2023 to USD 65.26 billion in 2031. The market's growth is supported by the rising consumption of nutraceuticals, novel launches, and increasing investments by leading market players toward expanding their customer base and improving their manufacturing capabilities. The rising collaborations, mergers, and acquisitions among nutraceutical CDMOs across the globe to expand their global presence and strengthen their footprints in their existing locations are also boosting the global nutraceuticals CDMO market.

Increasing technological advancements in nutraceutical developments is one of the major factors augmenting product demand, which in turn is increasing the dependency on nutraceutical contract development and manufacturing organizations (CDMOs). Ongoing advancements in technology, including novel delivery systems and encapsulation techniques, are revolutionizing the nutraceuticals sector. Such technological innovations are aiding in enhancing the targeted delivery of nutraceutical ingredients as well as their bioavailability and stability, making them more appealing to customers.

Additionally, the leading market players are also working on securing grants and funding to expand their sites in different regions across the globe. Such efforts are also expected to provide lucrative growth opportunities for the nutraceutical CDMO market. In August 2024, Lonza Group Ltd. secured a USD 38.6 million (£30 million) grant for their biologics site in the United Kingdom. The Department for Science, Innovation, and Technology issued the grant to the company under their subsidy scheme, the Life Sciences Innovative Manufacturing Fund. Such grants are expected to aid the major market players in focusing their efforts on research and development activities and strengthening their operations in different regions.

Furthermore, the growing popularity of direct-to-consumer channels and e-commerce platforms is also facilitating access to nutraceuticals across the globe by allowing consumers to purchase nutraceutical products online and bypassing traditional retail platforms conveniently. This increased accessibility is further propelling the demand for nutraceutical products and positively influencing the expansion of the nutraceuticals CDMO market.

Novel Launches Drive Market Growth

Various CDMOs across the globe are entering the nutraceuticals industry with a broad range of products and formulations. In March 2023, Akums Drugs and Pharmaceuticals Ltd., India-based CDMO, entered the nutraceuticals sector with a wide range of formulations that aid patients in combatting common ailments. The customized range of products launched by the company aims to provide palatable and convenient dosage forms for geriatrics, adults, and pediatrics compared to the traditional options. The products range from immunity boosters and multivitamins to products that support urinary health, sleep, hair health, and morning sickness, among others. The company's new gummy formulations are produced at their Nutravedics plant and offer an easy-to-consume and differentiated nutraceutical option.

Additionally, various CDMOs are engaging in mergers and acquisitions to ensure that they are able to provide high-quality services to their clients. Due to the increasing consumer interest in nutraceuticals, the requirement for novel launches and the introduction of differentiated and innovative products is rising. The growing popularity of personalized nutrition also propels the requirement for novel launches and increases the reliance on nutraceutical CDMOs to meet consumer demand.

Rising Requirement for Nutraceuticals Support Market Expansion

The growing emphasis on preventive healthcare and the increasing requirement for medical interventions is one of the major factors boosting the demand for nutraceuticals in different regions across the globe. The increasing awareness among the general population about the importance of preventive healthcare can be attributed to the rising cases of lifestyle-related diseases and the rapid expansion of the aging population. According to a survey conducted by LocalCircles.com, Inc., in February 2024, 7 out of 10 consumers surveyed confirmed that they regularly took various nutraceuticals ranging from dietary supplements to vitamins. The survey also showed that approximately 71% of Indian households consume nutraceuticals regularly. This increased requirement is thus augmenting the requirement for nutraceutical CDMOs to allow major businesses to meet the growing product demand. Additionally, the increasing adoption of a sedentary lifestyle and eating habits along with low levels of exercise is augmenting the prevalence of lifestyle-related disorders, thus increasing the reliance on nutraceutical products and bolstering the global nutraceuticals CDMO market demand.

Tablets and Capsules Account for Significant Market Share

The convenience and reliability of tablets and capsules support the segment's growth. Tablets and capsules also ensure precise dosing, allowing the patients to receive the desired amount of active ingredients for the desired results. Additionally, various leading market players and research institutions across the globe are increasingly focusing on launching new nutraceutical tablets and capsules. In June 2024, IDRS Labs Pvt. Ltd. and the Department of Atomic Energy (DAE) launched nutraceutical/ food supplement tablets AKTOCYTE to improve the quality of life of patients suffering from cancer and undergoing radiotherapy. The tablet received approval from the Food Safety and Standards Authority of India (FSSAI) and is supported by decades of research at the DAE. The tablets have also shown remarkable results across pelvic cancer patients who are observing side effects from radiotherapy. The organizations hope that the culminated launch of the product will go a long way in preventing damage to health tissues from radiation during cancer treatment.

Furthermore, the expansion of the segment can also be attributed to the excellent protection and stability offered by the tablets and capsules for the enclosed ingredients.

North America Holds Major Market Share

The rapid expansion of the market in the region can be attributed to the rising health consciousness among the general population and growing requirements for efficient manufacturing processes and innovative formulations to meet the evolving healthcare needs of the general population. The leading market players are also expanding their regional presence, further providing lucrative growth opportunities. In February 2023, Lonza Group Ltd. announced opening a new laboratory in Massachusetts, United States, as part of their plan to expand their early development services division in North America. The expanded services are allowing the company to aid customers in addressing and identifying potential problems with drug candidates.

The growth of the North America nutraceuticals CDMO market can also be attributed to the growing awareness about the different advantages of consuming nutraceuticals, such as improved immune system functioning, improved gut health, and reduced inflammation. The rising popularity of nutraceuticals can also be attributed to their accessibility and affordability. Thus, the increasing consumption of nutraceuticals is propelling the requirement for CDMOs to meet the rising consumer requirements.

Future Market Scenario (2024-2031F)

As per the global nutraceuticals CDMO market analysis, the market is expected to grow significantly over the coming years due to strategic partnerships, technological innovations, and rising consumer demand for preventive healthcare solutions. The growing emphasis on personalized nutrition is bolstering the expansion of the functional foods and beverages industry, further providing lucrative growth opportunities to the market. The rising nutritional requirements of the rapidly growing population are also expected to propel the requirement for nutraceutical CDMOs. According to estimates from the United Nations, the global population is estimated to reach 8.5 billion by 2030. Furthermore, the growing threat of various chronic diseases and the recent pandemic have shown the importance of preventive healthcare, boosting the demand for nutraceuticals from different regions across the globe. Consumers across the globe are increasingly consuming immunity-boosting supplements, resulting in a significant shift in market behavior and shopping patterns. In order to meet the growing requirement for nutraceuticals, the dependency on CDMOs is expected to increase, positively influencing the market's rapid expansion.

Meanwhile, due to the rising regulatory requirements, companies are expected to prioritize CDMOs with advanced technologies and robust quality assurance capabilities.

Key Players Landscape and Outlook

The key players in the market are actively investing in the expansion of their production facilities in different regions across the globe and are also engaging in mergers and acquisitions to expand their global footprint. In September 2024, Lonza Group Ltd. completed the planned expansion of their mid-scale microbial manufacturing facility in Switzerland, which recently received the good manufacturing practice (GMP) license after a successful audit by the Swiss Agency for Therapeutic Products. The facility houses two 4,000 L fermenters and provides commercial manufacturing capacity with automation principles in its core operations. This expansion strengthens the company's service offerings and allows it to adapt to its customers' life cycle scenarios and demands.

Furthermore, in March 2024, the company secured a manufacturing plant from F. Hoffmann-La Roche Ltd to corner contracts on next-generation medicines in a USD 1.2 billion deal. The California-based facility houses a bioreactor capacity of approximately 330,000 liters. With the help of the facility, the company aims to increase its sales from 12% to 15% over the next four years, from the previous window of 11% to 13%.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Nutraceuticals CDMO Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Dosage Form
    • 4.2.1.1. Tablets and Capsules
    • 4.2.1.2. Powder
    • 4.2.1.3. Others
  • 4.2.2. By Service
    • 4.2.2.1. Product Formulation and Development
    • 4.2.2.2. Manufacturing and Packaging
    • 4.2.2.3. Research and Development
    • 4.2.2.4. Regulatory Compliance
    • 4.2.2.5. Others
  • 4.2.3. By Company Size
    • 4.2.3.1. Small Companies
    • 4.2.3.2. Mid-Sized Companies
    • 4.2.3.3. Large Companies
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Dosage Form
  • 4.3.2. By Service
  • 4.3.3. By Company Size
  • 4.3.4. By Region

5. North America Nutraceuticals CDMO Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Dosage Form
    • 5.2.1.1. Tablets and Capsules
    • 5.2.1.2. Powder
    • 5.2.1.3. Others
  • 5.2.2. By Service
    • 5.2.2.1. Product Formulation and Development
    • 5.2.2.2. Manufacturing and Packaging
    • 5.2.2.3. Research and Development
    • 5.2.2.4. Regulatory Compliance
    • 5.2.2.5. Others
  • 5.2.3. By Company Size
    • 5.2.3.1. Small Companies
    • 5.2.3.2. Mid-Sized Companies
    • 5.2.3.3. Large Companies
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Nutraceuticals CDMO Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Dosage Form
        • 5.3.1.2.1.1. Tablets and Capsules
        • 5.3.1.2.1.2. Powder
        • 5.3.1.2.1.3. Others
      • 5.3.1.2.2. By Service
        • 5.3.1.2.2.1. Product Formulation and Development
        • 5.3.1.2.2.2. Manufacturing and Packaging
        • 5.3.1.2.2.3. Research and Development
        • 5.3.1.2.2.4. Regulatory Compliance
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Company Size
        • 5.3.1.2.3.1. Small Companies
        • 5.3.1.2.3.2. Mid-Sized Companies
        • 5.3.1.2.3.3. Large Companies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Nutraceuticals CDMO Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Nutraceuticals CDMO Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Nutraceuticals CDMO Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Nutraceuticals CDMO Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Catalent, Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Lonza Group Ltd.
  • 20.3.3. Robinson Pharma, Inc.
  • 20.3.4. Aenova Holding GmbH
  • 20.3.5. Soho Flordis International Pty Limited
  • 20.3.6. NutraPakUSA
  • 20.3.7. International Flavors & Fragrances Inc. (Health Wright Products)
  • 20.3.8. NutraScience Labs
  • 20.3.9. INPHARMA S.p.A.
  • 20.3.10. INW Manufacturing, LLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer